Stock CPMV MOSAIC IMMUNOENGINEERING, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Mosaic ImmunoEngineering, Inc.

Equities

CPMV

US61945M1018

Delayed OTC Markets
Other stock markets
 11:20:30 2024-06-07 am EDT 		5-day change 1st Jan Change
0.5 USD 0.00% Intraday chart for Mosaic ImmunoEngineering, Inc. +19.05% -16.67%
May. 14 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 19 Mosaic Immunoengineering, Inc. Announces Demise of Gloria Felcyn, Independent Director and Member of Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
AQ
Mosaic Immunoengineering, Inc. Announces Demise of Gloria Felcyn, Independent Director and Member of Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee
CI
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K
PU
Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU
CI
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)
AQ
Mosaic Immunoengineering, Inc. Announces Nicole Steinmetz, Ph.D., to Resign as A Member of the Board of Directors and Acting Chief Scientific Officer
CI
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Mosaic ImmunoEngineering Inc. Auditor Raises 'Going Concern' Doubt
CI
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Mosaic ImmunoEngineering Inc. Academic Collaborators Receives Grants Totaling $4.3 Million from NCI Focuses on its Novel Immuno-Oncology Platform
CI
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CPMV Stock
  4. News Mosaic ImmunoEngineering, Inc.